Last updated: February 20, 2026
This report provides an overview of the primary suppliers manufacturing Bystolic (nebivolol), a selective beta-1 blocker used to treat hypertension.
Manufacturing and Supply Chain Overview
Bystolic is produced primarily through generic formulations, and its patent expired in 2013. As a result, multiple suppliers now produce the drug, leading to increased competition and availability.
Top Global Suppliers
| Company Name |
Country of Origin |
Manufacturing Status |
Market Presence |
| Mylan (a Viatris company) |
United States |
Full-scale generic producer |
Significant global supply |
| Teva Pharmaceutical Industries |
Israel |
Generic manufacturing |
Extensive distribution |
| Sandoz (Novartis division) |
Switzerland |
Generics and biosimilars |
Global markets |
| Lupin Limited |
India |
Large-scale generic production |
Growing presence |
| Sun Pharmaceuticals |
India |
Broad pharmaceutical portfolio |
International reach |
Additional Suppliers
- Aurobindo Pharma (India)
- Dr. Reddy’s Laboratories (India)
- Hetero Drugs (India)
- Zydus Cadila (India)
These companies produce nebivolol in various formulations, including tablets with different dosages (e.g., 5 mg, 10 mg).
Distribution Channels
Suppliers distribute through wholesale distributors, pharmacy chains, hospitals, and direct contracts with healthcare providers. Suppliers often engage in licensing agreements to expand market reach into emerging economies.
Regulatory Status and Approvals
Suppliers generally hold regulatory approvals from major agencies:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Central Drugs Standard Control Organization (India)
These approvals ensure compliance with safety, efficacy, and manufacturing standards for their generic nebivolol products.
Market Dynamics and Trends
- Increased demand from aging populations assesses for hypertension management.
- Price competition from multiple generic manufacturers has reduced costs.
- Entry of biosimilar-like formulations remains limited, focusing on small-molecule generics.
Summary
Bystolic's supply chain involves multiple global generic manufacturers, with key players including Mylan (Viatris), Teva, Sandoz, Lupin, and Sun Pharmaceuticals. The drug's patent expiration in 2013 facilitated broadening production and distribution, reducing prices and increasing access worldwide.
Key Takeaways
- The primary suppliers are Mylan, Teva, Sandoz, Lupin, and Sun Pharmaceuticals.
- Production is concentrated mainly in India and Israel, with significant presence in the U.S. and Europe.
- Regulatory approvals from FDA, EMA, and Indian authorities ensure compliance.
- Increased competition has driven down prices and expanded access.
FAQs
1. Which companies are the leading suppliers of Bystolic globally?
Mylan (Viatris), Teva, Sandoz, Lupin, and Sun Pharmaceuticals are the primary producers.
2. Are biosimilars available for nebivolol?
No, nebivolol is a small-molecule drug; biosimilars are not applicable.
3. What is the main manufacturing region for generic nebivolol?
India is the largest manufacturing hub, followed by Israel and other countries.
4. Does Bystolic have active patent protection now?
The patent expired in 2013, allowing generic manufacturers to produce the drug.
5. How do regulatory approvals impact supply?
Approvals from FDA, EMA, and Indian authorities standardize quality, allowing broader distribution.
References
- Food and Drug Administration. (2022). Drug approvals and labeling. https://www.fda.gov/drugs
- European Medicines Agency. (2022). Marketing authorization approvals. https://www.ema.europa.eu/
- Indian Central Drugs Standard Control Organization. (2022). Drug registration data. https://cdsco.gov.in/
- IMS Health. (2021). Global pharmaceutical market analysis.
